Please type a plus sign (+) inside this box \longrightarrow	F
	, ,

Substitute for form 1449A/B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

1 of

Complete if Known				
Application Number	10/588,323			
Filing / 371(c) Date	February 16, 2007			
First Named Inventor	MAGILAVY			
Group Art Unit	1644			
Examiner Name	Phillip Gambel			
Attorney Docket Number	253780			

OTHER - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *			
	C624	JEFFERIS et al., IgG-Fc-medicated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation, <i>Immunological Reviews</i> 1998, 163: 59-76 (June 1998)				
	C625	JANEWAY et al., Immunobiology, The immune system in health and disease, Third Edition, Current Biology Ltd./Garland Publishing Inc., New York, pp. 7:4-7:7 (1997)				
0.1 40000						

Examiner Signature	Date Considered	

^{*} If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.